Prospective study evaluates FIB-4 index performance in fibrosis prediction for chronic hepatitis B and MASLD patients, highlighting its limitations.
Key Points
FIB-4 index displays robust fibrosis prediction in chronic hepatitis B patients, yet shows reduced effectiveness in those with MASLD.
ROC analysis for FIB-4 yielded an AUC of 0.86 in chronic hepatitis B patients, but only 0.61 in the MASLD subgroup, indicating reduced predictive performance.
The study included 109 chronic hepatitis B and 64 MASLD patients, analyzing liver stiffness via elastography and FIB-4 scores.
These findings call for improved fibrosis prediction tools to better address the challenges faced by patients with concurrent chronic hepatitis B and MASLD.